By Dr. Dimitrios Zarkadas, Ph.D. Director, Merck & Co Control of physical attributes of amorphous Active Pharmaceutical Ingredients (APIs) can be challenging due to processability issues, their wide variation...
Dr. Dimitrios Zarkadas has 20 years of experience in API development, commercialization and lifecycle management. He is currently leading API lifecycle management and development activities for the Merck Animal...
By Dr. Shuang Chen, Ph.D. Senior Principal Scientist, AbbVie In recent years, more and more structurally diverse and complex molecules have been developed to tackle difficult but attractive drug...
Shuang Chen is currently a Senior Principal Scientist in Small Molecule CMC Development organization at AbbVie. He has over 18 years of pharmaceutical development experience with specialties in molecular...
Dr. Noalle Fellah is a Senior Scientist in the Crystallization Technology Lab (CTL) within Chemical Research and Development (CRD) at Pfizer, Inc. Noalle earned her PhD in Chemistry from...
By Mr. James D. Fostinis, Ph.D. Drug Substance Technologies Engineer, Amgen Quench crystallization approaches provide unique opportunities to design and control crystallization of pharmaceutically-relevant compounds, which can help streamline...
Jim Fostinis is an Engineer within the Drug Substance Technologies – Synthetics team in Process Development at Amgen. During his time at Amgen, Jim has focused on small molecule...
By Prof. Jerry Heng, Ph.D. Professor, Department of Chemical Engineering at Imperial College The purification of high molecular weight new modalities such as peptides, for their use in biopharmaceutical...
